HBsAg Inhibitor Synthesis via Chiral Auxiliaries
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HBV drugs are ineffective in reducing HBsAg levels, and existing surface antigen inhibitors face challenges such as complex synthesis processes and high costs due to isomer separation.
Innovation Solution
Development of novel 11-oxo-7,11-dihydro-6H-benzo[f]pyrido[1,2-d][1,4]oxazepine-10-carboxylic acid derivatives that act as hepatitis B virus surface antigen inhibitors, with a focus on simplifying the synthetic process and improving drug-like properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing surface antigen inhibitors are used, then anti-HBV activity is achieved, but synthesis process becomes complex and cost increases due to isomer separation
Solution Approach 1:
The patent extracts and eliminates the problematic isomer separation step from the synthesis process by designing a synthetic route that inherently produces the desired enantiomer, thereby simplifying the process while maintaining anti-HBV activity
Solution Approach 2:
The patent employs chiral auxiliary agents or asymmetric synthesis methods in the preliminary steps of the synthesis process to establish the correct stereochemistry early on, preventing the formation of unwanted isomers and eliminating the need for subsequent separation
2Object-affected harmful factors
If carbon atom on seven-membered ring is replaced by oxygen, then aqueous solubility increases and oxidative metabolism risk lowers, but synthesis complexity may increase
Solution Approach 1:
The patent systematically modifies molecular parameters by replacing carbon with oxygen at specific positions in the seven-membered ring, adjusting the molecule's physical and chemical properties to improve solubility and metabolic stability while managing synthesis complexity through targeted modifications
3Ease of manufacture
If chiral center is prepared using commercial amino acid, then synthesis becomes simpler and more economical, but enantiomer purity may be reduced
Solution Approach 1:
The patent uses chiral resolving agents or chiral chromatography as intermediary means to separate and purify the desired enantiomer from the mixture produced by commercial amino acid synthesis, achieving high enantiomer purity while maintaining the simplicity of using commercial starting materials
Data Source
AI summary
Disclosed in the present invention is a new 11-oxo-7,11-dihydro-6h-benzo-[f]pyrido[1,2-d][1,4]azepine oxepin-10-carboxylic acid derivative serving as a hepatitis B virus surface antigen inhibitor. Specifically disclosed are a compound represented by formula (V) or a pharmaceutically acceptable salt thereof, and applications of the compound represented by formula (V) or the pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof in the treatment of viral hepatitis B.